This protocol is for the use of CliniMACS CD34 Reagent System in a single patient with relapsed AML. Patient received salvage chemo and planned stem cell boost for cytopenias. Since donor is a haplo, plan is to give CD34 selected cells with some t cell add back. Read more
A PHASE 1B/2, MULTICENTER, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXd), A B7-H3 ANTIBODY-DRUG CONJUGATE (ADC), IN COMBINATION WITH ATEZOLIZUMAB WITH OR WITHOUT CARBOPLATIN AS FIRST-LINE INDUCTION OR MAINTENANCE, IN SUBJECTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) Read more
A Multi-Center Phase II Randomized Trial of Immunotherapy versus Chemoimmunotherapy Guided by Circulating Tumor DNA Based Molecular Response on Patients with Metastatic NSCLC Read more
A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab with Atezolizumab plus Bevacizumab in Previously-Treated Advanced Non- squamous NSCLC Read more
An expanded access program for mobocertinib in Non Small Cell Lung Cancer exon20 insertion mutation patients Read more
Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib Read more
A Single-Center Experience with Tarlatamab for Small Cell Carcinoma of Pulmonary and Extrapulmonary Origin Read more
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants with Resected Stage II, IIIA,IIIB (N2) Non-small Cell Lung Cancer Read more
